CLSD

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts for traders to stay updated on stock market movements.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories from Benzinga reporters.

Company Announcement: Clearside Biomedical, Inc. will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, featuring CEO George Lasezkay and CMO Victor Chong.

Innovative Technology: The company focuses on delivering therapies to the back of the eye using its patented SCS Microinjector, with ongoing development of treatments for conditions like wet AMD and geographic atrophy.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Company Progress and Trials: Clearside Biomedical is advancing its CLS-AX program into pivotal Phase 3 trials for wet AMD, with a focus on flexible dosing intervals and personalized treatment plans, while maintaining alignment with the FDA.

Financial Outlook and Challenges: The company reported $20 million in cash as of year-end 2024, sufficient to fund operations into Q4 2025, but faces challenges in securing additional funding for the Phase 3 program amidst competitive pressures in the market.

Earnings Reports: Major companies such as Gevo, Lululemon, and Winnebago are set to report earnings today, with expected stock price movements indicated by options prices.

Implied Moves: The anticipated stock price changes range significantly, with PDS Biotechnology showing a potential move of +/- 125% and Gevo at +/- 29.27%, highlighting the volatility around earnings announcements.

Upcoming Earnings Reports: Major companies such as GameStop, Lululemon, and Chewy are set to report earnings this week, with TipRanks providing expected stock price movements based on options volatility.

Options Trading Insights: The article explains the concept of "volatility crush," where option prices rise before earnings announcements due to uncertainty and drop significantly afterward, highlighting the risks associated with options trading.

Suprachoroidal Drug Delivery Advances: Clearside Biomedical is making significant progress in suprachoroidal drug delivery for treating macular diseases, with six abstracts accepted for presentation at the ARVO 2025 Meeting, highlighting the potential of their CLS-AX formulation for neovascular age-related macular degeneration (wet AMD).

Innovative Injection Technology: The company's SCS Microinjector enables targeted and compartmentalized delivery of therapeutics directly to the retina, aiming to improve patient outcomes by minimizing side effects and enhancing treatment efficacy.

Clearside Biomedical's Innovations: Clearside Biomedical is advancing the treatment of wet age-related macular degeneration (AMD) through its suprachoroidal delivery platform, particularly with its lead product CLS-AX, which aims to provide longer-lasting therapy and improved safety compared to traditional anti-VEGF treatments.

Regulatory Strategy and Clinical Trials: The company discussed its regulatory strategies and upcoming Phase 3 trial plans for CLS-AX at the 2025 Wet AMD & Diabetic Eye Disease Summit, emphasizing the need for innovative approaches in a growing market valued over $12 billion.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Investment Opportunity: JonesResearch recommends buying shares of Clearside Biomedical (CLSD) with a $6 price target, citing overblown concerns regarding adverse events from the ODYSSEY trial and highlighting the potential of Intravitreal Duravyu as a leading treatment in its category.

Data-Driven Insights: Investors are encouraged to utilize TipRanks' Smart Score tool for informed stock decisions and to track their investments against top Wall Street analysts' recommendations.

Clearside Biomedical's Presentation: Clearside Biomedical's Chief Medical Officer, Dr. Victor Chong, presented critical insights on drug development and regulatory processes for retinal diseases at the Edridge Green Lecture, which was published in the journal Eye. The lecture emphasized advancements in clinical trial design and the importance of academic-industry collaborations.

Company Overview: Clearside Biomedical focuses on innovative therapies for eye diseases using its patented SCS Microinjector for targeted delivery. The company is advancing its pipeline, including a Phase 3 program for its lead product, CLS-AX, aimed at treating wet age-related macular degeneration.

Clearside Biomedical's Advancements: Clearside Biomedical showcased its suprachoroidal delivery technology and pipeline programs at various medical meetings, including the Asia-Pacific Vitreo-Retina Society Congress and the Ophthalmology Innovation Summit, highlighting positive results from the ODYSSEY trial for wet AMD treatment.

Innovative Delivery Approach: The company emphasizes its proprietary SCS Microinjector system, which allows targeted drug delivery to the back of the eye, potentially improving treatment efficacy while minimizing side effects, with ongoing developments for products like CLS-AX and XIPERE.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Partnership Announcement: Clearside Biomedical has partnered with Arctic Vision and Santen Pharmaceutical to commercialize ARVN001 (XIPERE) for treating uveitic macular edema in China, enhancing the reach of their suprachoroidal space delivery platform.

Clinical Progress: Arctic Vision is advancing ARVN001 through regulatory reviews and positive clinical trial results in the Asia-Pacific region, aiming to improve treatment options for patients with ocular diseases.

Financial Results Announcement: Clearside Biomedical, Inc. will report its third quarter 2024 financial results on November 12, 2024, followed by a webcast and conference call at 4:30 p.m. ET for discussion and updates.

Company Overview: Clearside is focused on innovative therapies for eye diseases using its patented SCS Microinjector® for targeted drug delivery, with ongoing development of its lead program, CLS-AX, for wet AMD treatment.

CLS-AX Phase 3 Development: Clearside Biomedical announced positive results from the Phase 2b ODYSSEY trial for CLS-AX, a treatment for wet AMD, demonstrating extended duration and reduced injection frequency, leading to plans for Phase 3 development.

SCS Microinjector Technology: The company's SCS Microinjector allows targeted delivery of therapies to the back of the eye, showcasing versatility in multiple presentations at the American Academy of Ophthalmology meeting, with significant interest from physicians.

Real-time Trading Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.

Trial Results: Clearside Biomedical's ODYSSEY Phase 2b trial for CLS-AX in treating wet AMD achieved both primary and secondary outcomes, showing stable visual acuity and retinal thickness over six months compared to aflibercept.

Safety Profile and Efficacy: The treatment demonstrated a well-tolerated safety profile with reduced injection frequency by approximately 84%, and no serious adverse events reported through 36 weeks.